Cycling peptides — when to come off, when to stay on
8 min read · Uplevel editorial
Somewhere in the online conversation about peptides, "cycle" became a universal instruction. Take it for twelve weeks, take four weeks off. Or five weeks on, two weeks off. The specific numbers vary, but the underlying assumption doesn't: everything needs to be cycled, and cycling is what keeps it working. If you believe that, you'll apply it uniformly, which means you'll cycle things that don't need cycling and fail to cycle things that do. The rule sounds responsible. It's actually a blunt instrument applied to a situation that requires precision.
Cycling means deliberate on-and-off periods rather than continuous use. The biological justification for cycling — when it exists — is that some compounds drive receptor systems that adapt downward under sustained activation, or that some compounds trigger feedback loops that will eventually work against the therapeutic goal if the signal never rests. The justification varies by compound. In some cases it's well-supported by evidence. In some cases it's extrapolated from related systems. In some cases it's just gym culture applied to a clinical tool.
Sermorelin is a compound with a genuine cycling rationale. Sermorelin is a GHRH analog — it acts on the pituitary's GHRH receptor to stimulate the natural pulsatile release of growth hormone. The pulsatile nature of that release is not incidental; it's how the system is designed. Growth hormone is released in discrete pulses, predominantly during deep sleep, and the pituitary responds to both stimulatory signals (GHRH) and inhibitory signals (somatostatin) in a rhythmic pattern. When you administer exogenous GHRH signaling continuously, over a long enough period, the pituitary's receptor density and sensitivity can begin to adapt. The biological mechanism here is receptor downregulation — the same process that makes any receptor system less responsive when it's chronically stimulated. This is why providers who prescribe Sermorelin typically build in off periods: not because Sermorelin is harmful, but because the pituitary needs intervals of normal baseline activity to maintain its responsiveness. Running Sermorelin continuously without any rest period risks getting diminishing returns over time. The off period is part of the therapeutic design. Your prescribing provider can tell you what protocol makes sense for your specific situation.
GHRPs — growth hormone-releasing peptides — operate through the ghrelin receptor and have similar cycling considerations. The ghrelin receptor also downregulates with sustained stimulation. The pattern of diminishing returns over continuous use is well enough documented in the research context that most providers building GH-axis protocols build in structured rest periods. The logic is the same: the feedback loop is real, and the cycling protocol is how you respect it.
NAD+ sits at the opposite end of the spectrum. NAD+ is not a signaling ligand that binds a receptor and triggers a downstream cascade. It is a cofactor — a molecule that other enzymes need in order to function. The sirtuins require it. The PARP enzymes require it. The electron transport chain requires it. When you replete NAD+, you are restoring the biochemical substrate that cellular machinery runs on. There is no receptor that downregulates in response to adequate NAD+ levels. There is no feedback loop that adapts to suppress NAD+ availability when you provide more of it. You don't build tolerance to a cofactor the way you can build tolerance to a receptor agonist. Continuous use of NAD+ supplementation isn't fighting a feedback mechanism. It's maintaining a substrate. The cycling imperative doesn't apply in the same way, and most providers who work with NAD+ manage it as a maintenance strategy rather than a pulsed protocol.
GHK-Cu is another example that doesn't follow the cycling template. GHK-Cu is a copper-binding tripeptide studied for its role in collagen synthesis, wound healing, skin remodeling, and anti-inflammatory signaling. It acts locally and regeneratively — it's not driving a systemic endocrine feedback loop. There is no pituitary axis involved. There is no receptor population being driven toward downregulation by continuous exposure. The research on GHK-Cu suggests that its effects are regenerative and broadly tissue-supportive, and the pattern of evidence doesn't indicate that continuous exposure creates the kind of adaptive resistance you see with secretagogues. Whether you run it continuously or in pulses depends more on your clinical goal than on a blanket cycling rule.
GLP-1 receptor agonists — semaglutide, tirzepatide — occupy their own category entirely. The concept of "cycling" as applied to these compounds doesn't map cleanly onto the bodybuilding-derived framework. Discontinuation of a GLP-1 agonist isn't a planned off period to preserve receptor sensitivity; it's a clinical decision about whether to maintain a therapeutic dose, reduce to a lower maintenance dose, or stop based on your individual health goals and your provider's assessment. The weight regain that often follows discontinuation isn't a cycling failure — it's a reflection of the fact that the biology being addressed by the medication (hunger signaling, gastric motility, insulin response) reasserts itself when the compound is removed. How and when to step down from a GLP-1 agonist is a prescribing decision, not a supplement cycling protocol. Your prescribing provider should be guiding that transition explicitly.
The three questions that actually determine whether a compound needs cycling are these. First: does this compound act on a receptor, and does that receptor downregulate under sustained stimulation? If yes, cycling is likely part of good protocol design. GHRPs and GHRH analogs: yes. NAD+: no receptor involved. GHK-Cu: different mechanism. Second: is there a feedback loop — an axis or a homeostatic mechanism — that will adapt to sustained stimulation and work against the therapeutic goal? The GH axis has this property. It's why Sermorelin cycling is not just convention — it's physiology. Systems without that adaptive feedback don't require cycling for the same reason. Third: is there any evidence of a tolerance pattern in the compound-specific literature? Some compounds have direct human research on extended use. Others have only in vitro or animal data. The confidence level of the cycling recommendation should match the confidence level of the evidence.
"Everyone needs to cycle off" is too simple. "You can take this forever without managing it" is also too simple. The truth is compound-specific, and the principles that determine the answer — receptor dynamics, feedback loops, tolerance patterns — are knowable. You just have to ask the right questions about the right compound rather than applying a single template to every molecule in your protocol.
Cycling isn't a ritual. It's a biological response to a specific type of pharmacodynamic reality. Where that reality exists, cycling is genuine protocol design. Where it doesn't, cycling is just a habit borrowed from a different context. Knowing which situation you're in is the thing worth getting right.